COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 87 of 318 for:    warfarin AND anticoagulation

D-dimer to Guide Anticoagulation Therapy in Patients With Atrial Fibrillation (DATA-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03261284
Recruitment Status : Enrolling by invitation
First Posted : August 24, 2017
Last Update Posted : March 7, 2019
Information provided by (Responsible Party):
Wuhan Asia Heart Hospital

Brief Summary:
This was a prospective, three arms, randomized controlled study.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Thrombosis Hemorrhage Anticoagulant Adverse Reaction Drug: Dabigatran Etexilate 150 MG [Pradaxa] Drug: Warfarin Pill Not Applicable

Detailed Description:
D-dimer testing is performed in AF Patients receiving warfarin therapy (target INR:1.5-2.5) in Wuhan Asia Heart Hospital. Patients with elevated d-dimer levels (>0.5ug/ml FEU) were SCREENED AND RANDOMIZED to three groups at a ratio of 1:1:1. First, NOAC group,the anticoagulant was switched to Dabigatran (110mg,bid) when elevated d-dimer level was detected during warfarin therapy.Second,Higher-INR group, INR was adjusted to higher level (INR:2.0-3.0) when elevated d-dimer level was detected during warfarin therapy. Third, control group, patients with elevated d-dimer levels have no change in warfarin therapy. Warfarin is monitored once a month by INR ,and dabigatran dose not need monitor. All patients were followed up for 24 months until the occurrence of endpoints, including bleeding events, thrombotic events and all-cause deaths.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: D-dimer to Determine Intensity of Anticoagulation to Reduce Clinical Outcomes in Patients With Atrial Fibrillation
Estimated Study Start Date : March 1, 2019
Estimated Primary Completion Date : February 28, 2020
Estimated Study Completion Date : May 30, 2020

Arm Intervention/treatment
Experimental: DOAC group
Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).
Drug: Dabigatran Etexilate 150 MG [Pradaxa]
Dabigatran Etexilate 150mg,bid
Other Name: Pradaxa

Experimental: Higher-INR group
Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.
Drug: Warfarin Pill
Add warfarin dose according to INR values.

No Intervention: Control group
Patients continue previous strategy without change.

Primary Outcome Measures :
  1. Thrombotic events [ Time Frame: 24 months ]
    Stroke, DVT, PE, Peripheral arterial embolism, ACS etc.

  2. hemorrhagic events [ Time Frame: 24 months ]
    cerebral hemorrhage,Gastrointestinal bleeding etc.

Secondary Outcome Measures :
  1. all-cause deaths [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with non-valvular atrial fibrillation
  • Receiving warfarin therapy

Exclusion Criteria:

  • Patients who had suffered from recent (within 3 months) myocardial infarction, ischemic stroke, deep vein thrombosis, cerebral hemorrhages, or other serious diseases.
  • Those who had difficulty in compliance or were unavailable for follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03261284

Layout table for location information
China, Hubei
Zhang litao
Wuhan, Hubei, China, 430022
Sponsors and Collaborators
Wuhan Asia Heart Hospital
Layout table for investigator information
Study Director: Zhenlu ZHANG, MD,PhD Wuhan Asia Heart Hospital
Layout table for additonal information
Responsible Party: Wuhan Asia Heart Hospital Identifier: NCT03261284    
Other Study ID Numbers: 2017-P-032
First Posted: August 24, 2017    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wuhan Asia Heart Hospital:
Nonvalvular atrial fibrillation
Direct thrombin inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action